Canadian Cancer Trials Group Bulletins

Group Administrators Office

Leadership of the Sarcoma Site Committee

The Canadian Cancer Trials Group's Central Office is very pleased to inform you that Drs. Thierry Alcindor, McGill University in Montreal, and Torsten Nielsen, University of British Columbia, have agreed to take on the role of Co-Chairs of the Canadian Cancer Trials Group's Sarcoma Disease Site Committee (DSC). Drs. Alcindor and Nielsen will succeed Dr. Vivien Bramwell, who has recently retired from the University of Calgary.

Dr. Bramwell has chaired the Sarcoma DSC since 1985, and is one of the longest serving site chairs with the Canadian Cancer Trials Group. Through Dr. Bramwell's exemplary leadership, the Committee has made important contributions to many clinical trials which have changed practice for Canadian patients diagnosed with sarcoma. These have included participating in Canadian Cancer Trials Group SRC.1, an international trial evaluating imatinib for the management of gastrointestinal stromal tumours (Canadian Study Chair: Dr. Martin Blackstein), and Canadian Cancer Trials Group SR.2, an Canadian Cancer Trials Group-led trial evaluating the timing and long-term toxicity of radiation for patients with surgically resectable soft tissue sarcoma (Canadian Study Chair: Dr. Brian O'Sullivan). She has been a leader in developing national and international linkages with other sarcoma groups, which have enabled the successful work of the Canadian Cancer Trials Group including the Canadian Sarcoma Group, the EORTC Soft Tissue and Bone Sarcoma Group, US cooperative groups and, more recently, with the Sarcoma Alliance for Research Through Collaboration (SARC). This collaboration with SARC has culminated in the activation of a new clinical trial evaluating a novel agent for patients with high grade soft tissue sarcoma (Canadian Cancer Trials Group SR.6) (Canadian Study Chair: Dr. T. Alcindor). She has been a mentor to numerous young investigators, many of whom have subsequently assumed leadership roles as Canadian Cancer Trials Group study and committee chairs. We sincerely thank Vivien for her nearly three decades of vision and leadership.

We are pleased to welcome Drs Thierry Alcindor and Torsten Nielsen as the new Sarcoma DSC Co-Chairs. Dr. Alcindor obtained his M.D. from the Université d'Etat d'Haiti and M.Sc. from the University of Oxford, UK. He undertook residency training at Yale University School of Medicine and fellowship training at Tufts University School of Medicine, Boston. He is an associate professor at McGill University, Montreal, and holds a staff position at Montreal General Hospital and Royal Victoria Hospital, Montreal. His main research interest is clinical trials in digestive cancers and sarcomas, for which he holds multiple grants and has published extensively. He is a member of Canadian Cancer Trials Group's Sarcoma Disease Site Committee, and is distinguished by consistently being the lead accruer across several Canadian Cancer Trials Group sarcoma clinical trials.

Dr. Torsten Nielsen is a clinician-scientist and professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia and pathologist at the Vancouver General Hospital focusing on musculoskeletal pathology. He is also Co-Director of the Genetic Pathology Evaluation Centre at Vancouver Hospital, where he has undertaken a number of tissue microarray and gene expression profiling research initiatives. He has published over a 100 research articles and holds numerous external grants. He is a member of the Canadian Cancer Trials Group's Sarcoma Disease Site Committee, as well as the Correlative Sciences Tumour Biology Committee and the Investigational New Drug Executive Committee.

These new leadership roles will become effective immediately.

Once again, heartfelt thanks to Vivien for her many years of service to the Canadian Cancer Trials Group. We very much look forward to the leadership Thierry and Torsten will provide to the Sarcoma Disease Site Committee and to Canadian Cancer Trials Group in the years ahead, and want to thank them for taking on these Co-Chair roles.